Zydus Lifesciences Drug Patent Portfolio

Zydus Lifesciences's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Reasons a major cancer medication may soon become significantly more affordable in India

18 Jan, 2026

Delhi High Court permits Zydus to market a more affordable biosimilar of the cancer medication Nivolumab for the benefit of the public.

13 Jan, 2026

Zydus receives approval from India to market a cost-effective cancer medication amid a patent conflict with Squibb.

13 Jan, 2026

Delhi High Court Approves Sale of Nivolumab Biosimilar at 70% Lower Price, Offering Hope to Cancer Patients

13 Jan, 2026